Evidence map›Paper›PMID 30503203›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2018

TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling.

Alan R Wolfe, R Jeffrey Neitz, Mark Burlingame, Brian M Suzuki, K C Lim, Mark Scheideler, David L Nelson, Leslie Z Benet, Conor R Caffrey

Open access · goldAbstract read
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Enhancing schistosomiasis drug discovery approaches with optimized proteasome substrates.Protein science : a publication of the Protein Society · 2025
    Article
  3. Article
  4. Chemical modulation ofWellcome open research · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Anthelmintics - From Discovery to Resistance III (Indian Rocks Beach, FL, 2018).International journal for parasitology. Drugs and drug resistance · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Alan R WolfeDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, 533 Parnassus Ave, San Francisco, CA, 94143, USA; Center for Discovery and Innovation in Parasitic Diseases, University of California, 1700 4th St, San Francisco, CA, 94158, USA.
R Jeffrey NeitzCenter for Discovery and Innovation in Parasitic Diseases, University of California, 1700 4th St, San Francisco, CA, 94158, USA; Department of Pharmaceutical Chemistry, University of California, 1700 4th St, San Francisco, CA, 94158, USA.
Mark BurlingameDepartment of Pharmaceutical Chemistry, University of California, 1700 4th St, San Francisco, CA, 94158, USA.
Brian M SuzukiCenter for Discovery and Innovation in Parasitic Diseases, University of California, 1700 4th St, San Francisco, CA, 94158, USA; Department of Pathology, University of California, 1700 4th St, San Francisco, CA, 94158, USA.
K C LimCenter for Discovery and Innovation in Parasitic Diseases, University of California, 1700 4th St, San Francisco, CA, 94158, USA; Department of Pathology, University of California, 1700 4th St, San Francisco, CA, 94158, USA.
Mark ScheidelerHuman First Therapeutics LLC, 9600 Dewitt Drive, Ste 1, Silver Spring, MD, 20910, USA.
David L NelsonPro-Rectory of Research and Graduate Study, Federal University of the Valleys of Jequitinhonha and Mucuri, 39100-000, Diamantina, MG, Brazil.
Leslie Z BenetDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, 533 Parnassus Ave, San Francisco, CA, 94143, USA; Center for Discovery and Innovation in Parasitic Diseases, University of California, 1700 4th St, San Francisco, CA, 94158, USA.
Conor R CaffreyCenter for Discovery and Innovation in Parasitic Diseases, University of California, 1700 4th St, San Francisco, CA, 94158, USA; Department of Pathology, University of California, 1700 4th St, San Francisco, CA, 94158, USA. Electronic address: ccaffrey@ucsd.edu.
University of California, San Francisco · USUniversidade Federal dos Vales do Jequitinhonha e Mucuri · BR

Funding

An automated high throughput phenotypic screen for schistosomiasis drug discoveryR01AI089896 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARKIN, MICHELLE, CAFFREY, CONOR · 2010 to 2012
$1.3M
Exploring statins as a small molecule therapy for treatment of schistosomiasisR21AI107390 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARKIN, MICHELLE · 2013 to 2014
$421k
NIAID NIH HHS R01 AI089896NIAID NIH HHS R21 AI107390
6 · The paper itself

Abstract

Treatment of schistosomiasis relies precariously on just one drug, praziquantel (PZQ). In the search for alternatives, 15 S-[2-(alkylamino)alkane] thiosulfuric acids were obtained from a previous research program and profiled in mice for efficacy against both mature (>42-day-old) and juvenile (21-day-old) Schistosoma mansoni using a screening dose of 100 mg/kg PO QDx4. One compound, S-[2-(tert-butylamino)-1-phenylethane] thiosulfuric acid (TPT sulfonate), was the most effective by decreasing female and male worm burdens by ≥ 90% and ≥46% (mature), and ≥89% and ≥79% (juvenile), respectively. In contrast, PZQ decreased mature female and male worm burdens by 95% and 94%, respectively, but was ineffective against juvenile stages. Against 7-day-old lung-stage worms, TPT sulfonate was only effective at twice the dose decreasing female and male burdens by 95 and 80%, respectively. Single oral doses at 400 and/or 600 mg/kg across various developmental time-points (1-, 7-, 15-, 21- and/or 42 day-old) were consistent with the QD x4 data; efficacy was strongest once the parasites had completed lung migration, and female and male burdens were decreased by at least 90% and 80%, respectively. In vitro, TPT sulfonate is inactive against the parasite suggesting a pro-drug mechanism of action. In mice, TPT sulfonate is fully absorbed and subject to rapid, non-CYP-mediated, first-pass metabolism that is initiated by desulfation and yields a series of metabolites. The initially-formed free thiol-containing metabolite, termed TP thiol, was chemically synthesized; it dose-dependently decreased S. mansoni and Schistosoma haematobium motility in vitro. Also, when administered as a single 50 mg/kg IP dose, TP thiol decreased 33-day-old S. mansoni female and male burdens by 35% and 44%, with less severe organomegaly. Overall, TPT sulfonate's efficacy profile is competitive with that of PZQ. Also, the characterization of a parasiticidal metabolite facilitates an understanding and improvement of the chemistry, and identification of the mechanism of action and/or target.

Indexed as

Administration, OralAnimalsArylsulfonatesDisease Models, AnimalDrug DiscoveryFemaleLiverMaleMetabolomicsMicePraziquantelProdrugsSchistosoma haematobiumSchistosoma mansoniSchistosomiasis mansoniSchistosomicidesArylsulfonatesPraziquantelProdrugsSchistosomicidesAlkylaminoalkanethiosulfuric acidAnthelminticDrug dispositionDrug metabolismSchistosomaSchistosomiasis

Identifiers

PMID30503203
PMCPMC6287543
OpenAlexW2900966870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.